UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT PURSUANT TO SECTION 13 OR 15(d)
OF
THE SECURITIES EXCHANGE ACT OF 1934
December
20, 2011
Date
of Report (Date of earliest event reported)
BOSTON
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
333-164785 |
27-0801073 |
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
33 South Commercial Street, Manchester, NH 03101
(Address
of principal executive offices) (Zip Code)
(978) 886-0421
(Registrant’s
telephone number, including area code)
(Former Name or
Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
(d) On December 20, 2011, the Board of Directors (the “Board”) of Boston Therapeutics, Inc. (the “Company”) elected Henry J. Esber as a member of the Board to fill a vacancy on the Board.
Henry J. Esber, Ph.D. has been a Principal in Esber D&D consulting since
2005. From 2003 to 2005, Dr. Esber was a Senior Consultant, Business
Development at Charles River Labs, Discovery and Development Services.
From 2005 to 2006, Dr. Esber was a consultant and from 2006, he was
Senior Vice President and Chief Business Officer for Bio-Quant which he
had co-founded. Dr. Esber was also the co-founder of BioSignature
Diagnostics, Inc. and Advanced Drug Delivery, Inc. He serves on the
Scientific Advisory Boards of several biotechnology companies and is the
author of more than 130 technical publications. Dr. Esber has more than
35 years of experience in the areas of oncology/tumor immunology and
immunotherapy as well as strong knowledge in the field of toxicology and
regulatory affairs. Dr. Esber received a B.S. degree in biology/pre-med
from the College of William and Mary, an M.S. degree in public health
and parasitology from the University of North Carolina, and a Ph.D. in
immunology/microbiology from West Virginia University Medical
Center. Dr. Esber was previously a Director of the Company from
September 2009 through December 2010.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BOSTON THERAPEUTICS, INC. |
|||
|
|||
Date: | December 22, 2011 | By: |
/s/ David Platt, Ph.D. |
David Platt |
|||
Chief Executive Officer |
2